cd19/cd20/bcma car t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2024 (NCT06446128)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06732232 | Early Phase 1 (Phase 1) | Dec 12, 2024 | Shanghai Cell Therapy Group Co.,Ltd |
| NCT06446128 | Early Phase 1 (Phase 1) | Apr 1, 2024 | Shanghai Cell Therapy Group Co.,Ltd, Shanghai University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Cell Therapy Group Co.,Ltd | For profit | 2 | 2 | 1 | 2024 |
| Shanghai University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1